Amplimune receives regulatory approval
Tuesday, September 22 2020 4:05 am
Agilis are proud to be able to distribute Amplimune to the NZ market on behalf of NovaVive Inc.
Designed to reduce the clinical signs and mortality associated with E.COLI K99 and to enhance innate immunity to fight bacterial infections without the use of antibiotics, Amplimune is providing New Zealand veterinarians and farmers with an effective antibiotic alternative in young calves.
Please check out our website for more information on this innovative product.